Sign in

CIK 0001799448

  • Non-accelerated filer
  • Smaller reporting company

Aligos Therapeutics, Inc.

Sign in to watch
Ticker
ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 800-466-6059
Business address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-09-08 Quan Lucinda Y. Grant or award · Stock Option (Right to Buy) +48,000 48,000
2023-03-15 Quan Lucinda Y. Grant or award · Stock Option (Right to Buy) +78,750 78,750
2022-07-07 Quan Lucinda Y. Grant or award · Stock Option (Right to Buy) +52,500 52,500
2022-02-04 Quan Lucinda Y. Grant or award · Stock Option (Right to Buy) +105,000 105,000
2022-02-04 Quan Lucinda Y. Grant or award · Stock Option (Right to Buy) +26,250 26,250
2020-12-01 Quan Lucinda Y. Grant or award · Stock Option (Right to Buy) +200,000 200,000
2020-10-20 Quan Lucinda Y. Conversion +6,835 6,835
2020-10-20 Quan Lucinda Y. Conversion +1,697 8,532
2020-10-20 Quan Lucinda Y. Conversion +726 9,258
2020-10-20 Quan Lucinda Y. Conversion · Series A Preferred Stock −6,835 0
2020-10-20 Quan Lucinda Y. Conversion · Series B-1 Preferred Stock −1,697 0
2020-10-20 Quan Lucinda Y. Conversion · Series B-2 Preferred Stock −726 0

Page 1 of 1 · 12 trades